Bilal Ahmad, MD
Hematology & Oncology · Oklahoma City, OKNPI 1275845778
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,145 of the $4,432 with a category attached, or 71.0%. 42 manufacturers reported payments, led by Amgen at 25.9% of the total.
Across 164 payments — averaging $27.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Pfizer$448
- Novartis$335
- AstraZeneca$208
- Merck$198
- Eisai Inc.$157
- plus $2K from 36 others
What the payments were for
- Speaking & faculty fees$97422%
- Food & beverage$3,14571%
- Education$3137%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $1,148 |
| Pfizer | 20 | $448 |
| Novartis | 17 | $335 |
| AstraZeneca(2 entities) | 12 | $208 |
| Merck | 11 | $198 |
| Eisai Inc. | 3 | $157 |
| Sanofi | 7 | $155 |
| Johnson & Johnson Vision Care, Inc. | 1 | $142 |
| Astellas Pharma US Inc | 7 | $132 |
| Sun Pharmaceutical Industries Inc. | 1 | $123 |
| E.r. Squibb & Sons, L.L.C. | 8 | $120 |
| Johnson & Johnson | 7 | $107 |
| Genentech USA, Inc. | 6 | $107 |
| Daiichi Sankyo Inc. | 4 | $91 |
| Gilead | 5 | $91 |
| Incyte Corporation | 4 | $73 |
| AbbVie | 3 | $67 |
| Ipsen Biopharmaceuticals, Inc | 4 | $65 |
| Verastem, Inc. | 4 | $60 |
| Lilly USA, LLC | 4 | $60 |
| Seagen Inc. | 3 | $53 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Tersera Therapeutics LLC | 2 | $41 |
| EMD Serono, Inc. | 2 | $40 |
| Bristol Myers Squibb | 2 | $35 |
| Array Biopharma Inc | 1 | $26 |
| Myovant Sciences Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $20 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Tesaro, Inc. | 1 | $20 |
| Geron Corporation | 1 | $18 |
| Sobi, Inc | 1 | $17 |
| Taiho Oncology, Inc. | 1 | $16 |
| CTI Biopharma Corp. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Dova Pharmaceuticals | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $14 |
| Coherus Oncology, Inc. | 1 | $14 |
| Epizyme, Inc. | 1 | $12 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMDELLTRA (AMG 757)$974
- Acuvue$142
- YONSA$123
- LENVIMA$122
How this compares
$4,432 in reported general payments places this provider in the 70th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 31 | $555,384 |
| PromactaEltrombopag Olamine | 15 | $399,740 |
| LorbrenaLorlatinib | 12 | $257,604 |
| PomalystPomalidomide | 12 | $251,595 |
| CalquenceAcalabrutinib Maleate | 16 | $228,740 |
| XtandiEnzalutamide | 14 | $189,942 |
| RydaptMidostaurin | 11 | $185,744 |
| Abiraterone Acetate | 29 | $76,852 |
| Sunitinib Malate | 14 | $67,381 |
| EliquisApixaban | 40 | $28,875 |
| XareltoRivaroxaban | 16 | $14,586 |
| Xtampza ErOxycodone Myristate | 19 | $7,403 |
| Tamoxifen Citrate | 144 | $4,181 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 75 | $2,044 |
| Megestrol Acetate | 37 | $1,235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisPromacta, Rydapt | $335 | $585,48526 claims |
| Bristol Myers SquibbRevlimid | $35 | $555,38431 claims |
| PfizerLorbrena, Eliquis | $448 | $286,47952 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $120 | $251,59512 claims |
| AstraZenecaCalquence | $208 | $228,74016 claims |
| Astellas Pharma US IncXtandi | $132 | $189,94214 claims |
| Johnson & JohnsonXarelto | $107 | $14,58616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Oklahoma City
- Romeo MandanasOklahoma City$160K
- Mohammad RazaqOklahoma City$56K
- Sami IbrahimiOklahoma City$41K
- Jennifer Holter-ChakrabartyOklahoma City$39K
- Hassan HatoumOklahoma City$23K
- Abdul Rafeh NaqashOklahoma City$23K
- Taha Al-JuhaishiOklahoma City$23K
- Adanma Anji Ayanambakkam AttanathiOklahoma City$16K
- Robert ReynoldsOklahoma City$15K
- Sadia ChohanOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.